Exelixis (NASDAQ:EXEL) was downgraded by TheStreet from a “b” rating to a “c+” rating in a research note issued on Thursday.
Several other brokerages have also issued reports on EXEL. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Cann reiterated a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 target price for the company in a research report on Tuesday, January 2nd. Finally, UBS upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 27th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $34.10.
Exelixis (NASDAQ EXEL) traded down $0.11 during mid-day trading on Thursday, hitting $24.64. 2,923,150 shares of the stock were exchanged, compared to its average volume of 2,894,309. Exelixis has a one year low of $18.03 and a one year high of $32.50. The company has a market capitalization of $7,333.60, a price-to-earnings ratio of 50.29, a P/E/G ratio of 1.35 and a beta of 1.96.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 EPS for the quarter, meeting analysts’ consensus estimates of $0.12. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. The company had revenue of $120.10 million during the quarter, compared to analyst estimates of $120.25 million. During the same period last year, the business earned $0.12 earnings per share. Exelixis’s revenue was up 54.8% compared to the same quarter last year. analysts anticipate that Exelixis will post 0.57 EPS for the current fiscal year.
In other Exelixis news, Director Lance Willsey sold 30,000 shares of Exelixis stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $23.91, for a total transaction of $717,300.00. Following the transaction, the director now directly owns 483,273 shares of the company’s stock, valued at $11,555,057.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Vincent T. Marchesi sold 15,000 shares of Exelixis stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $24.73, for a total transaction of $370,950.00. The disclosure for this sale can be found here. Insiders have sold 120,029 shares of company stock worth $3,158,287 over the last three months. Insiders own 5.10% of the company’s stock.
Several hedge funds have recently bought and sold shares of EXEL. American Century Companies Inc. increased its stake in shares of Exelixis by 426.4% in the fourth quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock worth $44,686,000 after buying an additional 1,190,691 shares during the period. Jennison Associates LLC increased its stake in shares of Exelixis by 38.1% in the fourth quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock worth $128,554,000 after buying an additional 1,167,758 shares during the period. Macquarie Group Ltd. increased its stake in shares of Exelixis by 811.5% in the third quarter. Macquarie Group Ltd. now owns 1,276,453 shares of the biotechnology company’s stock worth $30,928,000 after buying an additional 1,136,409 shares during the period. Smith Asset Management Group LP purchased a new position in shares of Exelixis in the fourth quarter worth $26,323,000. Finally, Wells Fargo & Company MN increased its stake in shares of Exelixis by 36.5% in the third quarter. Wells Fargo & Company MN now owns 3,042,694 shares of the biotechnology company’s stock worth $73,723,000 after buying an additional 814,177 shares during the period. 80.55% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/17/exelixis-exel-rating-lowered-to-c-at-thestreet.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.